-
Two Years In: New Long-Term Extension Data from PIVOT-HD for Votoplam
Latest News
-
Advances on many fronts in the battle against the protein that causes Huntington's disease
This fall sees exciting announcements from a number of companies focused on novel Huntingtin Lowering technologies, including Wave, PTC and Voyager
-
HDSA FAQ on the Roche/Genentech RG6042 program
HDSA's frequently asked questions factsheet about the huntingtin-lowering trial ASO program was so good we stole it (with permission)
-
Kids sometimes get Huntington’s disease too
Finally, a big study that shows what childhood HD looks like. This will help us work out if new drugs work in children too
-
Roche announces details of its 'pivotal' huntingtin-lowering study
The GENERATION-HD1 trial will test whether RG6042 – formerly Ionis-HTTRx – slows the progression of Huntington's disease
-
Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
The LEGATO-HD trial of laquinimod did not slow progression of Huntington's disease. Here's the lowdown.
-
HDBuzz Enrolls in Enroll-HD
As promised, HDBuzz's Jeff Carroll finally signed up for the Enroll-HD study. Learn more about this important global HD "observational study" here.
-
First Dolly, now Piglet; a new Huntington’s disease pig knock-in model confirmed
For the first time in HD research, an animal model has been created in pigs using 2 cutting edge DNA editing t
-
New collaboration seeks to speed Huntington's disease drug licensing
Critical Path Institute launches new initiative to get HD drugs licensed as quickly as possible
-
HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
Our friends at @hdsa have produced this really good Q&A document about the latest huntingtin-lowering news.
-
Exciting Experiments in "Open Science" by Huntington's Researchers
Brave scientists open their notebooks to help drive HD research at the risk of getting "scooped".
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
